Sildenafil Tablet, Film Coated
Product Images NDC 68071-2985

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Sildenafil (NDC 68071-2985). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2985 3)

Label for Sildenafil 100 mg tablets by NuCare Pharmaceuticals, Inc., showing a prescription drug container with 30 film-coated oral tablets. The label includes the product name, strength, quantity, manufacturer details, NDC code 68071-2985-3, and storage instructions at controlled temperature 68-77°F.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 1)

Chemical structure diagram of Sildenafil, the active ingredient in the 100 mg film-coated oral tablets produced by NuCare Pharmaceuticals, Inc. The image shows the molecular layout with labeled atoms and bonds characteristic of Sildenafil.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 2)

A line graph comparing systolic blood pressure changes (mmHg) over 24 hours post-dose between Sildenafil 100 mg and placebo. The x-axis shows time in hours post dose, and the y-axis shows systolic blood pressure. Two distinct trend lines represent the effects of Sildenafil and placebo over time.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 3)

A line graph depicting change in systolic blood pressure (SBP) over time post dose (hours) comparing two treatments: Doxazosin with Placebo and Doxazosin with Sildenafil 25 mg. The y-axis shows change in SBP (mmHg), and the x-axis shows time from 0 to 8 hours post dose.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 4)

A line graph depicting changes in systolic blood pressure (SBP) over time after dosing. The x-axis shows time post dose in hours (0 to 8), and the y-axis shows change in SBP in mmHg (from -50 to 40). Two lines compare Doxazosin plus Placebo and Doxazosin plus Sildenafil 50 mg, illustrating trends in blood pressure changes over the 8-hour period.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 5)

Line graph showing blood pressure changes in mmHg over 8 hours after dosing, comparing Doxazosin combined with Sildenafil 100 mg against Doxazosin combined with placebo. The x-axis represents time in hours after dosing; the y-axis indicates blood pressure change in mmHg.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 6)

A line graph depicting plasma concentrations (ng/ml) of a drug over time post-dose (hours). The x-axis represents time up to 24 hours, and the y-axis shows plasma concentrations ranging from 0 to 500 ng/ml. Data points are shown for a Treatment labeled as Commercial Tablet.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 7)

A bar chart showing the effect of sildenafil on maintenance of erection by baseline score. The x-axis represents baseline scores from 0 to 5, and the y-axis shows the percentage of patients at endpoint from 0% to 80%. Multiple bars per baseline score illustrate different categories labeled 0 to 5, indicating varied patient percentages corresponding to each category.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 8)

A bar chart showing the effect of placebo on maintenance of erection by baseline score. The x-axis represents baseline scores from 0 to 5, and the y-axis shows the percentage of patients at endpoint, ranging from 0 to 80%. Multiple bars for each baseline score category indicate different subgroup data coded by a legend showing values from 0 to 5.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 9)

A bar chart showing the percentage of patients reporting improvement across four treatment groups: Placebo (24%, n=463), Sildenafil 25 mg (63%, n=214), Sildenafil 50 mg (74%, n=391), and Sildenafil 100 mg (82%, n=380). The x-axis represents treatment groups, and the y-axis represents percentage improvement. Overall treatment p-value is less than 0.0001.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.